| Identification | Back Directory | [Name]
1H-Indol-7-amine, 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)- | [CAS]
1120332-55-9 | [Synonyms]
1H-Indol-7-amine, 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)- | [Molecular Formula]
C24H29N3O3S | [MOL File]
1120332-55-9.mol | [Molecular Weight]
439.57 |
| Chemical Properties | Back Directory | [Boiling point ]
736.2±60.0 °C(Predicted) | [density ]
1.319±0.06 g/cm3(Predicted) | [solubility ]
Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml | [form ]
Solid | [pka]
17.48±0.30(Predicted) | [color ]
Off-white to yellow | [Cosmetics Ingredients Functions]
ANTIOXIDANT
SKIN PROTECTING |
| Hazard Information | Back Directory | [Uses]
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research[1]. | [in vivo]
NecroX-7 (0-0.3 mg/kg, IV, once injection at 2-d intervals, for 2 weeks) significantly attenuates GVHD-related mortality and inhibits severe tissue damage[1].
NecroX-7 protects mice against lethal GVHD by reciprocal regulation of regulatory T/Th1 cells, attenuating systemic HMGB1 accumulation and inhibiting HMGB1-mediated inflammatory response[1]. | Animal Model: | Female BALB/c and C57BL/6 mice (Eight-week-old, with GVHD)[1] | | Dosage: | 0.03, 0.1, and 0.3 mg/kg | | Administration: | IV, once injection at 2-d intervals, for 2 weeks | | Result: | Observed statistically significant prolonged survival at doses ≥0.1 mg/kg: 30–60% of mice in these treatment groups survived for >50 d. Significantly improved clinical signs and prolonged survival, and the mice showed a reduction in clinical manifestations of acute GVHD, including weight loss, hunched posture, diarrhea, and ruffled fur. |
| [IC 50]
IL-6; TLR4 | [References]
[1] Im KI, et al. The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release. J Immunol. 2015 Jun 1;194(11):5223-32. DOI:10.4049/jimmunol.1402609 |
|
|